Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma

被引：0

作者：

Manfredi, G. F. ^{[1
,2
]}

Fulgenzi, C. A. M. ^{[2
]}

D'Alessio, A. ^{[2
,3
]}

Celsa, C. ^{[2
,4
,5
]}

Stefanini, B. ^{[2
,6
]}

Cheon, J. ^{[7
]}

Ang, C. ^{[8
]}

Marron, T. U. ^{[8
]}

Saeed, A. ^{[9
]}

Wietharn, B. ^{[9
]}

Pressiani, T. ^{[10
]}

Pinter, M. ^{[11
]}

Scheiner, B. ^{[11
]}

Huang, Yi-Hsiang ^{[12
,13
]}

Phen, S. ^{[14
]}

Naqash, A. Rafeh ^{[15
]}

Piscaglia, F. ^{[6
]}

Lin, R. Po-Ting ^{[16
,17
]}

Lin, C. -yen ^{[16
,17
]}

Dalbeni, A. ^{[18
,19
]}

Vivaldi, C. ^{[20
,21
]}

Masi, G. ^{[20
,21
]}

Thimme, R. ^{[22
]}

Vogel, A. ^{[23
,24
,25
]}

Schonlein, M. ^{[26
]}

von Felden, J. ^{[27
]}

Schulze, K. ^{[27
]}

Wege, H. ^{[27
]}

Galle, P. R. ^{[28
]}

Kudo, M. ^{[29
]}

Rimassa, L. ^{[10
,30
]}

Singal, A. ^{[14
]}

Sharma, R. ^{[2
]}

Cortellini, A. ^{[1
,31
]}

Chon, H. Jae ^{[7
]}

Burlone, M. ^{[32
]}

Pirisi, M. ^{[1
,32
]}

Pinato, D. J. ^{[2
,3
]}

机构：

[1] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy

[2] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Du Cane Rd, London, England

[3] Univ Piemonte Orientale, Div Oncol, Dept Translat Med, Novara, Italy

[4] Univ Palermo, Sect Gastroenterol & Hepatol, Dept Hlth Promot Mother & Child Care Internal Med, Palermo, Italy

[5] Univ Palermo, Dept Surg Oncol & Oral Sci Di Chir On S, Palermo, Italy

[6] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

[7] CHA Univ, Dept Internal Med, CHA Bundang Med Ctr, Med Oncol, Seongnam, South Korea

[8] Tisch Canc Inst, Mt Sinai Hosp, Div Hematol Oncol, Dept Med, New York, NY USA

[9] Kansas Univ, Div Med Oncol, Dept Med, Canc Ctr, Kansas City, KS USA

[10] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Humanitas Canc Ctr, Via A Manzoni 56, I-20089 Rozzano, Milan, Italy

[11] Med Univ Vienna, Div Gastroenterol & Hepatol, Dept Internal Med 3, Vienna, Austria

[12] Taipei Vet Gen Hosp, Div Gastroenterol & Hepatol, Dept Med, Taipei, Taiwan

[13] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Sch Med, Taipei, Taiwan

[14] Univ Texas Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA

[15] Univ Oklahoma, Med Oncol, Stephenson Canc Ctr, TSET Phase 1 Program, Oklahoma City, OK USA

[16] Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Linkou Med Ctr, Taoyuan, Taiwan

[17] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[18] Univ Verona, Dept Med, Gen Med C Unit, Verona, Italy

[19] Univ Verona, Liver Unit, Verona, Italy

[20] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy

[21] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy

[22] Univ Freiburg, Freiburg Univ Med Ctr, Dept Med Gastroenterol Hepatol Endocrinol & Infec, Fac Med, Freiburg, Germany

[23] UHN, Toronto Gen Hosp, Toronto, ON M5G 2C4, Canada

[24] Princess Margaret Canc Ctr, Toronto, ON, Canada

[25] Hannover Med Sch, Hannover, Germany

[26] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hamburg, Germany

[27] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Hamburg, Germany

[28] Univ Med Ctr Mainz, Dept Internal Med 1, Mainz, Germany

[29] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[30] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20072 Milan, Italy

[31] Fdn Policlin Univ Campus Biomed, Med Oncol, Rome, Italy

[32] AOU Maggiore Carita, Div Internal Med, Novara, Italy

来源：

DIGESTIVE AND LIVER DISEASE | 2024年 / 56卷

关键词：

D O I：

10.1016/j.dld.2024.01.012

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

OC-11

引用

页码：S8 / S9

页数：2

共 50 条

[11] Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
Yano, Shigeki
Kawaoka, Tomokazu
Johira, Yusuke
Miura, Ryoichi
Kosaka, Masanari
Shirane, Yuki
Murakami, Serami
Amioka, Kei
Naruto, Kensuke
Ando, Yuwa
Kosaka, Yumi
Yamaoka, Kenji
Kodama, Kenichiro
Uchikawa, Shinsuke
Fujino, Hatsue
Ohno, Atsushi
Nakahara, Takashi
Murakami, Eisuke
Okamoto, Wataru
Yamauchi, Masami
Imamura, Michio
Mori, Keiichi
Arihiro, Kouji
Kuroda, Shintaro
Kobayashi, Tsuyoshi
Ohdan, Hideki
Aikata, Hiroshi
MEDICINE, 2021, 100 (42) : E27576
[12] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Galle, Peter R.
Ducreux, Michel
Kim, Tae-You
Kudo, Masatoshi
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed O.
Li, Daneng
Verret, Wendy
Xu, Derek-Zhen
Hernandez, Sairy
Liu, Juan
Huang, Chen
Mulla, Sohail
Wang, Yulei
Lim, Ho Yeong
Zhu, Andrew X.
Cheng, Ann-Lii
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20): : 1894 - 1905
[13] Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
Yang, Xu
Wang, Dongxu
Lin, Jianzhen
Yang, Xiaobo
Zhao, Haitao
LANCET ONCOLOGY, 2020, 21 (09): : E412 - E412
[14] Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
Chon, Young Eun
Cheon, Jaekyung
Kim, Hyeyeong
Kang, Beodeul
Ha, Yeonjung
Kim, Do Young
Hwang, Seong Gyu
Chon, Hong Jae
Kim, Beom Kyung
CANCER MEDICINE, 2023, 12 (03): : 2731 - 2738
[15] Organ-specific responses to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma.
Cheon, Jaekyung
Jung, Sanghoon
Kang, Beodeul
Kim, Hyeyeong
Kim, Chan
Chon, Hongjae
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[16] Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
Maesaka, Kazuki
Sakamori, Ryotaro
Yamada, Ryoko
Doi, Akira
Tahata, Yuki
Ohkawa, Kazuyoshi
Oshita, Masahide
Miyazaki, Masanori
Yakushijin, Takayuki
Nozaki, Yasutoshi
Matsumoto, Kengo
Tanaka, Satoshi
Kaneko, Akira
Iio, Sadaharu
Nawa, Takatoshi
Yamada, Yukinori
Morishita, Naoki
Usui, Takeo
Hiramatsu, Naoki
Doi, Yoshinori
Sakakibara, Mitsuru
Imanaka, Kazuho
Yoshida, Yuichi
Kodama, Takahiro
Hikita, Hayato
Tatsumi, Tomohide
Takehara, Tetsuo
PLOS ONE, 2023, 18 (02):
[17] Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma
D'Alessio, Antonio
Cammarota, Antonella
Zanuso, Valentina
Pressiani, Tiziana
Personeni, Nicola
Rimassa, Lorenza
EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (09) : 927 - 939
[18] Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma
Castet, Florian
Willoughby, Catherine E.
Haber, Philipp K.
Llovet, Josep M.
CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1827 - 1829
[19] Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma
Yano, Yoshihiko
Yamamoto, Atsushi
Mimura, Takuya
Kushida, Saeko
Hirohata, Seiya
Yoon, Seitetsu
Hirano, Hirotaka
Kim, Soo Ki
Hatazawa, Yuri
Momose, Kenji
Hayashi, Hiroki
Kado, Takuo
Nishi, Katsuhisa
Tanaka, Hidenori
Matsuura, Takanori
Yoshida, Ryutaro
Asaji, Naoki
Yasutomi, Eiichiro
Shiomi, Yuuki
Minami, Akihiro
Komatsu, Shohei
Fukumoto, Takumi
Ueda, Yoshihide
Kodama, Yuzo
JGH OPEN, 2023, 7 (07): : 476 - 481
[20] Regorafenib for patients with progression of advanced hepatocellular carcinoma after treatment with atezolizumab plus bevacizumab: a case series
Kang, Wendi
Fu, Hongjiang
Luo, Yingen
Noreika, Danielle M.
Cong, Tianhao
Li, Hang
Yang, Zhengqiang
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (02) : 780 - 787

← 1 2 3 4 5 →